Travere Therapeutics Inc. (TVTX) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Travere Therapeutics Inc. (TVTX) slipped -0.54% to $50.57 as options desks priced 52% call premium vs. 48% put protection around the $50 max-pain magnet. Solid 96% profit margin (-13% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, October 26, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The C
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual endothelin and
SAN DIEGO, October 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pa
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TVTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TVTX. Explore sector supply chains on /butterfly.
Why TVTX Stock slipped -0.54% Today — RQD Quant Desk Flash. Solid 96% profit margin (-13% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.